FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Result of General Meeting
3 November 2025
Result of General Meeting held on 3 November 2025
AstraZeneca PLC (the 'Company') announced that at the General
Meeting ('GM') of shareholders held earlier today, shareholders
approved the resolution to adopt new articles of association of the
Company, as required to
proceed with the harmonisation of the Company's equity listing
structure. As proposed in the Circular and Notice of GM circulated
on 29 September 2025, the Resolution was decided by poll vote and
was passed as a special resolution.
|
|
Votes for
|
% of votes cast
|
Votes against
|
% of votes cast
|
Votes cast in total
|
Total votes cast as a % of issued share capital
|
Votes withheld
|
|
To adopt new articles of association of the Company in connection
with the harmonisation of its equity listing structure
|
1,222,275,967
|
99.36
|
7,861,875
|
0.64
|
1,230,137,842
|
79.33
|
2,628,613
|
Michel Demaré, Chair AstraZeneca said: "Today's significant
vote in favour of the Board's proposal demonstrates strong
shareholder support for AstraZeneca's harmonised listing structure
in London, Stockholm and New York. As the Company continues
to expand and invest in our growing markets, our new structure will
offer the flexibility to access the broadest available pool of
capital, including in the US, enabling more shareholders to
participate in AstraZeneca's exciting future."
Next steps and timetable
The expected timetable of principal events as set out in the
Circular and Notice of GM remains unchanged and is replicated
below. The following dates and times are indicative only and are
subject to change. If any of the dates set out in the timetable
change, the Company will give notice of this change by issuing an
announcement through a Regulatory News Service.
|
Expected date for termination of ADR Programme, delisting of
AstraZeneca ADSs and cancellation of the listing and trading of
AstraZeneca US Bonds on Nasdaq
|
2 February 2026
|
|
Expected time and date for commencement of trading in AstraZeneca
Shares and AstraZeneca US Bonds on the NYSE
|
By 8:00 a.m. (ET) on 2 February 2026
|
|
Expected date for the issuance of AstraZeneca DIs to relevant CREST
participant accounts
|
On or around 2 February 2026
|
|
Expected date for the issuance of statements of entitlement for
existing CSN Eligible Certificated Shareholders and CSN
Participants
|
By no later than 16 February 2026
|
A copy of the special resolution passed at the GM has been
submitted to the National Storage Mechanism for publication, and
will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Issued capital
As at 30 October 2025, the number of issued shares of the Company
was 1,550,712,906 ordinary
shares, which was the total number of shares entitling the holders
to attend and vote for or against the Resolution. In accordance
with the Company's Articles of Association, on a poll every member
present in person or by proxy has one vote for every share
held.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit www.astrazeneca.com and
follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here. For
Media contacts,
click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
03 November 2025
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|
